UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) shares rose 3.6% on Thursday . The stock traded as high as $12.06 and last traded at $12.09. Approximately 285,917 shares changed hands during trading, a decline of 43% from the average daily volume of 497,520 shares. The stock had previously closed at $11.66.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on URGN. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Monday, March 10th. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective on the stock. Finally, HC Wainwright decreased their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $38.20.
View Our Latest Stock Report on UroGen Pharma
UroGen Pharma Price Performance
The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock has a 50-day simple moving average of $10.54 and a 200 day simple moving average of $11.56. The stock has a market capitalization of $548.52 million, a price-to-earnings ratio of -3.78 and a beta of 1.12.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million. On average, equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.
Insider Activity
In other news, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company's stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.
Institutional Trading of UroGen Pharma
Several large investors have recently made changes to their positions in URGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of UroGen Pharma by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock valued at $231,000 after purchasing an additional 969 shares during the period. Rhumbline Advisers increased its stake in shares of UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock worth $546,000 after purchasing an additional 1,402 shares during the period. MetLife Investment Management LLC grew its holdings in UroGen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock valued at $242,000 after buying an additional 2,727 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in UroGen Pharma by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock worth $996,000 after buying an additional 3,024 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of UroGen Pharma by 24.6% during the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock worth $211,000 after buying an additional 3,920 shares during the last quarter. Institutional investors own 91.29% of the company's stock.
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
